Eli Lilly and Company $LLY Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,175,866 shares of the company’s stock after buying an additional 689 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Eli Lilly and Company were worth $1,410,361,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of LLY. Integrity Financial Corp WA raised its holdings in Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after purchasing an additional 8 shares during the period. Willner & Heller LLC raised its stake in shares of Eli Lilly and Company by 1.0% during the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after buying an additional 9 shares during the period. Aspiring Ventures LLC lifted its position in shares of Eli Lilly and Company by 3.7% during the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after buying an additional 9 shares in the last quarter. Wealthspan Partners LLC grew its stake in Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after acquiring an additional 9 shares during the period. Finally, Navigoe LLC increased its holdings in Eli Lilly and Company by 8.7% in the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after acquiring an additional 9 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO Dave Ricks said Lilly is capturing about 70% of new senior GLP-1 patients following Medicare coverage expansion, while oral GLP-1 drug Foundayo accounts for roughly one-third of new oral-treatment starts. The comments reinforce Lilly’s commercial leadership and suggest that expanded insurance coverage could materially enlarge the addressable market. Lilly CEO discusses Medicare GLP-1 market share
• Positive Sentiment: Lilly broke ground on a $6.5 billion Houston manufacturing facility that will produce active ingredients for Foundayo and other medicines. The investment supports the company’s planned oral GLP-1 rollout, strengthens domestic supply, and is expected to create more than 600 jobs, although the benefits will take time to materialize. Lilly Houston manufacturing facility
• Positive Sentiment: Investors remain bullish on Lilly’s long-term growth. Home Depot co-founder Ken Langone said the shares could reach $2,000 within three to four years, reflecting confidence in the company’s obesity portfolio and broader pipeline. Ken Langone bullish on Lilly
• Neutral Sentiment: Lilly received full FDA approval for Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer, adding support to its oncology franchise. The approval is strategically positive but likely less important to near-term valuation than the obesity business. Inluriyo FDA approval
• Negative Sentiment: Viking Therapeutics reported data indicating its VK2735 obesity drug preserved most weight loss with every-other-week or monthly dosing. The result drove strong interest in a potential competitor to Zepbound, raising concerns about future pricing, adherence, and market-share pressure for Lilly, although Viking still needs Phase 3 results and regulatory approval. Viking obesity drug maintenance data
• Negative Sentiment: Novo Nordisk’s CagriSema also produced favorable late-stage weight-loss data in a diabetes study, keeping competitive pressure high. Lilly’s $6.5 billion facility further increases near-term capital spending, which may temper enthusiasm despite strong long-term demand.

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 1.4%

NYSE:LLY traded down $16.45 during trading hours on Wednesday, hitting $1,153.69. The company had a trading volume of 2,153,958 shares, compared to its average volume of 3,016,686. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The company has a market cap of $1.09 trillion, a P/E ratio of 38.71, a P/E/G ratio of 1.44 and a beta of 0.50. The company has a 50-day moving average of $1,176.84 and a 200 day moving average of $1,079.50. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the firm earned $6.31 EPS. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts expect that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LLY. Jefferies Financial Group lifted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 23rd. Sanford C. Bernstein lifted their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. Cantor Fitzgerald raised their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,305.25.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.